Unknown PHASE2 INTERVENTIONAL 3-arm NCT01549093

Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)

A Randomized, Open Label, Controlled Study About Endostar Continued Pumping or Injecting Into Vein Combining With Gemcitabine-Carboplatin Versus Gemcitabine-Carboplatin Alone to Treat Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Hunan Province Tumor Hospital

Conditions Non-small Cell Lung Cancer

Interventions Gemcitabine(G) Carboplatin(C) Gemcitabine(G) Carboplatin(C) Endostar Gemcitabine,Carboplatin,Endostar

Updated 6 times since 2017 Last updated: Mar 22, 2015 Started: Aug 31, 2011 Primary completion: Jul 31, 2016 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-small Cell Lung Cancer, this trial is ongoing. The trial is conducted by Hunan Province Tumor Hospital and has accumulated 6 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
May 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Recruiting PHASE2

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hunan Province Tumor Hospital

Data source: Hunan Province Tumor Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China